Search

everythinglearnresearchcommunity

for

Search:↓

Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.

Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.

Protein tyrosine kinases are key in male pattern baldness, affecting skin structure, hair growth, and immune responses.

Drug repurposing shows promise for treating many medical conditions.

A man's bald spot grew hair after starting cancer treatment with gefitinib.

Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.

An 84-year-old man developed a rare scalp condition from a cancer drug but continued treatment as it was otherwise well tolerated.

Sorafenib is effective in treating Desmoid Tumor/Deep Fibromatosis.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

A woman's hair turned white after taking a cancer drug called dasatinib.

A new gene mutation may allow some piebaldism patients to regain skin color in white patches.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

MicroRNAs are crucial in controlling cell signaling, affecting cancer and tissue regeneration.

Nilotinib can cause keratosis pilaris, a skin condition.

VEGF helps squamous cell carcinoma grow in ways beyond just blood vessel formation.

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Skin cells and immune cells change in a skin condition called hidradenitis suppurativa, and a certain treatment can improve these changes.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

The drug combination was safe and showed promise in treating advanced tumors.

Nilotinib can cause generalized keratosis pilaris.

Imatinib mesylate can cause skin lightening, especially in Chinese patients, due to its effect on pigment production.

Certain genes and pathways are linked to the production of finer and denser wool in Hetian sheep.

A woman's hair turned gray and fell out after starting a cancer drug called imatinib mesylate.

Glycyrrhizic acid may help reduce unwanted hair growth.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Androgens increase growth factors in skin cells, which may lead to acne.

mEphA1 receptor tyrosine kinase is important for skin and hair development and may play a role in certain diseases.

The conclusion is that healthcare professionals should report adverse drug reactions to improve medication safety and patient care.